this story is saying that astrazeneca _ astrazeneca vaccine? yes. this story is saying that astrazeneca is - astrazeneca vaccine? yes. this story is saying that astrazeneca is doing i is saying that astrazeneca is doing tests in these african hot spots where you are seeing the omicron variant emerge. they are feeling confident they will be able to create a new vaccine which addresses this new variant. that is good news if this is a case they can roll that out it means scientists have a lot of experience in creating new vaccines in dealing with mutations. this is too surprising but it's good news, it's good news is coming and hopefully it's a case that they will get the vaccine soon and can roll it out when needed. it’s get the vaccine soon and can roll it out when needed.— out when needed. it's interesting, astrazeneca _ out when needed. it's interesting, astrazeneca teams _ out when needed. it's interesting, astrazeneca teams are _ out when needed. it's interesting, astrazeneca teams are conducting test in african hot spots so that there jab ca

astrazeneca's ceo was speaking to justin and emphasized how the astrazeneca vaccine produces t cells and he made this claim which causes upset. >> in the u.k., therwas a big peak of infections but not so many hospitalizations. in the u.k. of this vaccine was used to vaccinate older people, whereas in europe initially people thought t vaccine does not work in older people. >> president micron said -- mac ron said so. >> it could relate to the durability of the response especially in older people. this vaccine has been shown to stimulate t cells to higher degree in older people. >> on hospitalizations first, what he said is true. the top chart shows confirmed cases from january two today. the u.k. is the pink line. for the end of the year, the u.k. had more cases than other countries. the bottom chart shows hospitalizations and it is closer. more people were being hospitalized in the u.k. compared to other countries, but the gap is smaller. so was astrazeneca being used widely the reason? danny is a professor of immunology. >> obviously knew right with the astrazeneca vaccine which has

the real dragon london is astrazeneca. it is starting to move towards taking profits when it comes to the covid shots, but that is not where the damage has been done. their inspiration issues we need to talk about. are they frontloading some of those issues? that seems to be a drag at the moment. some of the pieces they are not -- they are talking about are not up to snuff in terms of expectations. astrazeneca down 7%. a huge drag on the ftse 100. alix: a big miss for that cancer drug which a lot of analysts highlighted. emily field, berkeley head of european pharmaceuticals equity research joins us. emily has an overweight rating on the stock. your take on earnings that are you sticking with a price target? emily: it is starting to look like with degree so there was a significant revenue shortfall. it does seem like that is driven by temporary inventory effects in china. the company was quite adamant the growth story there remains intact. what investors were struggling with is the integration issues. there are going to be

potentially, the astrazeneca impact on the elderly— the astrazeneca impact on the elderly population might be beneficial, which will be good for the older— beneficial, which will be good for the older people in this country with a — the older people in this country with a very, very high take—up of the vaccine _ with a very, very high take-up of the vaccine-— with a very, very high take-up of the vaccine. before we move on, i would like — the vaccine. before we move on, i would like to _ the vaccine. before we move on, i would like to ask _ the vaccine. before we move on, i would like to ask the _ the vaccine. before we move on, i would like to ask the both - the vaccine. before we move on, i would like to ask the both of- the vaccine. before we move on, i would like to ask the both of you, | the vaccine. before we move on, i | would like to ask the both of you, i don't know if you followed the news this evening. if possible, work from home, and scotland and northern ireland. there was a warning from nicola sturgeon about taking care into winter. as far as england goes, the

astrazeneca's ceo is pascal soriot. he was speaking tojustin webb on the today programme — and emphasised how its vaccine produces t—cells. this is the claim that's caused the upset. when you look at the uk, there was a big peak of infections but not so many hospitalisations relative to europe. in the uk, this vaccine was used to vaccinate all their people, whereas in europe initially, people thought the vaccine doesn't work... famously president macron said so. in particular as it relates to the durability of response, especially in older people, this vaccine has been shown to stimulate t—cells to a higher degree in older people. on hospitalisations first — what pascal soriot said is true. the top chart here shows confirmed cases from january to today. the uk is the pink line. particularly towards the end of the year the uk had significantly more cases than other countries in europe. the bottom chart shows hospitalisations. and there — it's much closer — more people were being hospitalised in the uk compare

so for joint function in february, and one of our portfolio company is producing astrazeneca, lexi, so we're completely open to partnership with different machines and ad windsor's in practice. and then as far as regulatory approval from russia, manufacturing manufacturers just didn't apply for approval in russia. so it's more of a question for me to still health. how's the processes? but what we as are jeff gwinnett, the world we a partner and was menu exchanged. we for example, in columbus trials in argent. gina showed that would make life like sheen increases . and she borders into cell responses sooner. foreign vaccine, ben pines. and today we had a great meeting, was our chinese colleagues on the investments to think about joint award on different maybe combination of backseat. so we open to partnerships and believe that like cine combos is a good same for the world. you mentioned that there are some concerns where the m r n, a vaccines being used in europe. we've seen the cobra numbers spiking, even though more people have been vaccinated this year than last year. it's happening

and then the vital work since and here and took him on the boat, johnson johnson and the astrazeneca and spiked come putting those 3 out of those that his us goodness is strongest. one. you have a chance that because that also have a stronger potential and that you felt a range. you might want to let the strong could drop in that amount of and they boy just knew that was a protection. we've also spoken to the head of the russian direct investment fund, which has overseen the global distribution of the sputnik v vaccine. he says, a range of different jobs is key to fighting the pandemic and new straits. i think it's very important to investigate because in your very a so far student has shown to be incredibly effective against all the different mutations. and we will share some good data, hopefully a little bit later on a greater efficacy against delta very. and so when you were and of course, has to be started, and we need to see how the shunt is exists and mixing site games in your area, but also weekend really quickly about vaccine when you very and if needed. and we believe that d

that is the biggest decline for astrazeneca since december, 2020. the other corporate story i have my eye is amc, and i feel this is the most meta-of all moves. amc, the meme stock favorite tweeting that they will accept bitcoin, ethereum when you make online payments and buy things that amc. this feels like the natural next step for them. tom: this is a nod to the meme investors who pushed up their stock 2000% year to date. they are looking at doge coin. the practicalities of using crypto, do you monitor prices? dani: that is true. it is a weird thing to think that if you bought a ticket with doge coin, you would have to pay with 100 doge coins. it is something like .03% of bitcoin is the cost of a ticket. the denomination factor maybe is more confusing, but amc said they are weighing their own cryptocurrency. maybe one amc coin equals one ticket. tom: nft's as well of their major films is something they are looking at. the confluence of movies, the silver screen, and crypto, and whether or not it is an inflation hedge. inflation in the u.s. runnin

francine: that was the astrazeneca chief executive. you can watch that full conversation a few weeks from now in the next episode of "leaders with lacqua." it was a timely interview. this is into the winter months. a big concern for politicians is do you make the vaccine mandatory? tom: we're seeing a similar thing from australia. another country that pushed this zero covid policy. they have walked back on that. the u.k. government is trying to ramp up boosters. francine: i have mine december 24. right before christmas. in my mind maybe two years ago, maybe the idea we get over the pandemic we can reopen and move on. it depends on country to country and the kind of vaccinations you have and the policies that you're deploy. it is very difficult to see the whole world come together in and out. you're going to have countries where you see lockdowns. tom: in the u.s., michigan for example very high rates. they are betting very much on the response in terms of the medication coming through from pfizer and others in 2022. francine: it depend

russia has a vaccine similar to the astrazeneca on the johnson & johnson vaccine. the so-called vector virus vaccine is to doses of that. that is what you get if you are in russia. the astrazeneca vaccine was primarily united kingdom and some other european countries. here the moderna vaccine as a u.s. vaccine the research for that vaccine was done at the national institutes of health, bitter and as a u.s. company that is u.s. product. it is interesting how it is played out. there's talk about that a little bit with anesthesia chloroform was the european it invented phenomena it was much more dangerous than to other agents, ether and nitrous oxide it was perpetuated much longer there is a nationalistic sense of pride they were the ones who invented it. >> do you think nationalist sense of pride is also driving vaccine use? i would imagine so, right? even though some of these vaccines work better than others it seems countries have developed vaccines are sticking with theirs. >> it certainly seems that way. yes it is interesting you think it would not necessarily be

and then you've got the antibodies from gsk, astrazeneca, wash, and regeneron, which may use some efficacy. certainly the one i'm most worried about. and then the others, time will tell. all of that will be clearer in two or three weeks. tom: such important context, sam fazeli, thank you, director of research at bloomberg intelligence. now, even before this new covid variant emerged in south africa, austria had taken measures to reduce covid. and the spread of covid by going into lockdown. bloomberg's lizzy burden has been analyzing restrictions across this nation. what do we know at this stage about what they have put in place over these measures? lizzy: tom, even before the latest measures were imposed, austrians were avoiding public spaces. the latest data show they are avoiding public transport and eating out less. tom: ok, and other measures that have been considered by governments across europe and what it may mean for households and retailers and consumers? lizzy: well, people are not just in austria, but in germany as well, going out less. and it's not just germany. it's also italy

so i chose johnson and johnson astrazeneca provides a long beach response that would allow to avoid spikes have been seen right now in europe in the u. s. because emma and they, and other no vital partnership will provide full long didn't unity than just hammer . and they'd acknowledge we, for example, in fumble trials in argentina showed that it's on nick like seeing increases ancient borders into cell responses sooner. foreign magazine and times. and today we had the great meeting was our chinese colleagues on the investments to think about joint award on different may be combination of maxine, so we open to partnerships and we believe's a different restrictions are based on vaccine ah, approvals are on that. a different function certificate should be interchangeable and acceptable. so i think the world needs to comp understanding that it's not so much about to what she and brand, it's about the level of anxious boy, this is a truly matters is sometimes very individual response of people. how quickly declines for different people. so, but really we need to put aside political and broken

since and here i'm talking only about johnson johnson and the astrazeneca and spike accompanying those 3 out of those. that is us putting it is the strongest one a chance that because that also help us john good a potential and that you felt orange. you might want to let the strong could drop in the amount of anti boy just knew that it was a protection it was western government pushed this citizens to get a boost a shot. will household musicians expressed opposition to rich nations extending their nok elation programs, while vaccination rates remain low in poor countries, across much of africa, for example, less than 10 percent of the population has had a single dose. no more vaccines should go to countries that have already vaccinated more than 40 percent of their population. until clover has the vaccines, it needs to help other countries get to know more boosters should be administered except to immunocompromised people. most countries with high vaccine coverage continue to ignore our call for a global moratorium on boosters. so a good plan and we discussed it with a professor molecu

and in the vital works since and here i'm talking only about johnson johnson and the astrazeneca and spiked a complaint. and those 3 out of those that is us goodness is strongest one when you get a chance that because that also have a stronger potential and that you felt orange, you might want to let the strong could drop in the amount of anti boy dis, new that was a protection now as well past the start to push their citizens to get a booster shot. the world health organization has expressed opposition though to rich countries extend bear inoculation program while vaccination rates is so low in poorer countries across much of africa. at the moment, less than 10 percent of the population has had a single days. no more vaccines should go to countries that have already vaccinated more than 40 percent of their population. until kovacs has the vaccines, it needs to help by their countries. get that to normal boosters should be administered except to immunocompromised pupil. most countries with high vaccine coverage continued to ignore our call for a global moratorium on boosters. we did

the astrazeneca vaccine does give a good boost, _ astrazeneca vaccine does give a good boost, albeit not as good as at the moderna _ boost, albeit not as good as at the moderna and pfizer—biontech vaccines _ moderna and pfizer—biontech vaccines. but it is still a good boost — vaccines. but it is still a good boost and _ vaccines. but it is still a good boost and we would advise that they have a _ boost and we would advise that they have a boost, rather than have no booster— have a boost, rather than have no booster dose all. lastly, we advise that children aged 12—15 years are offered _ that children aged 12—15 years are offered a — that children aged 12—15 years are offered a second dose of vaccine at the standard dose of 30 mcg of a pfizer—biontech vaccine, 12 weeks after their— pfizer—biontech vaccine, 12 weeks after their first dose. this is the same _ after their first dose. this is the same schedule as a16—17 —year—olds at the _ same schedule as a16—17 —year—olds at the moment. we are —— for 16 and 17 euros _ at the moment. we are —— fo

and then the vital work since and here and took him on the boat, johnson johnson and the astrazeneca and spiked company. those 3 out of those that his us goodness is the strongest one. get a chance that because that also have a stronger to potential and that you felt a range. you might want to let the strong could drop in the amount of and they boy just knew that was a protection. what is western governments to push their citizens to get a boost a shot? the world health organization has expressed opposition to rich in nations extending their inoculation program. while vaccination rates are, do remain very low in poorer countries across much of africa. for example, less than 10 percent of the population has had a single decks. no more vaccines should go to countries that have already vaccinated more than 40 percent of their population. until kovacs has the vaccines, it needs to help other countries get that to normal boosters should be i understood it except to immunocompromised people. most countries with high vaccine coverage continued to ignore our call for a global moratorium on b

so we have some evidence, for instance, from a trunk hold, tackle in dumb astrazeneca that if you are at haven't had the infection before you get these antibodies early. that are your risk of death or hospitalization is greatly reduced. but on your so value, these antibodies act like a vaccine they, they give you the anti bodies directly, and that protection might last for up to a year. now, you might say, well, why do we need that? and we put vaccines when the problem is if you've got cancer, if you having chemotherapy, if you got on other immune a suppressing drugs, if you thought they had an organ transplant, you perhaps can't rely on being able to make those antibodies for yourself. and whilst vaccinations great in lifting lockdown for you and me to some other people that becomes a prison sentence because they can't get asked about any more because there are lots of people and they haven't managed a good enough noun response. so this is, these new treatments are very, very good news. i think the people such as that because it releases them from their own, so self imposed, locked d

and then finally, the mentally they relied on one company astrazeneca and then it got a live in the one production which was the sentiment situation. and yeah, so i mean how, how kovacs suppose that they can that one company was it or say them, or anybody, how can they for why, you know they produce in on those is for all know, on middle income countries, it was just not possible. it was not, you know, somebody and they did it that way. so if those were to happen and, you know, find them with saying that, you know, that hardly sold anything get low. i mean, in the middle income countries, and in that they are all the same size or just be not that they have been given. and then you may, you know, concerned about making profit in this market. i can't believe we're still having this conversation a year later, mac, mariani, but it's important to us without breaking the monopoly or know how we wouldn't have the same compensation. i was saying last year. we will have the this year. well, it has it next year, and i think if we do, i'll come back to you and talk to you about it. okay. then. oka

does it where mix your drinks and i was, you start with astrazeneca, you'll then get pfizer for your booster. what is that about the, the vaccinations that make it better to have different ones as you go through the the program? well, i wish i knew the onset because i probably get some medical prize for it. it's not widely understood. this is a phenomenon known as immuno mentation. the vaccine of course, pokes your body to recognise one specific barrow protein. and you thought that if you've got kobe to whatever you would only respond to that particular protein. but in fact that the, getting the virus and the vaccine interact to augment a much broader range of immune responses. so that to phenomena say nodes immuno mentation. and how it works isn't fully understood, operate to say, but it does work. so and mixing and matching does seem to be valuable. less come to your work, profess montgomery, as a, an intensive care, a physician on the walls. you're on money of treatments as no being greatly of meant it. we 1st had the satellite treatments last year, then those the antibody treatme

they haven't seen and other than the viral, maxine or just put nick, so i chose johnson and johnson astrazeneca provides a long being you'll response that would allow to avoid spikes is a, be a seen right now in europe in the us because emma and they and then the vital partnership will provide full long been unity just and we're in a technology. we for example, in columbus trials in argent. jima showed that it's nick, like seeing increases ancient borders into cell responses sooner. foreign maxine and times and today we had the great meeting was our chinese colleagues on the investments to think about joint award on different maybe combination of maxine, so we all want to partnerships and we believe that different restrictions are based on like seeing aah, approvals, our own that a difference, like she's certificate and she'll be interchangeable and acceptable. so i think the world needs to comp understanding that it's not so much about what she and brand, it's about the level of anxious boy, this is a truly mattress, is sometimes very individual response of people how quickly declines for diff

and astrazeneca vaccine. it was a replication defective adenovirus. adenovirus is a common cold virus. you can render so it can't reproduce itself and then you can put the gene in this boy lacked. and he was given that product, that gene as parts of an experience and he had essentially like a sensic like syndrome, where his immune system was overreacted and his blood pressure dropped and he basically died of what looked like bacterial sepsis but it was really an overactive immune response and nobody why that was. and eventually they did figure it out and one particular protein and immune system overwhelmed him. and with that, then the so called car t therapy where you can take someone's t cells out of the body and engineer it so can kill cancer cells. this is another penn phenomena. one girl received that therapy and she had the same symptoms jesse had. except this time you knew what happened to jesse. and this time you had a monochromal antibody to neutralize that interleukin 6 protein that had gone out of control. out of that gelsinger tragedy came

the astrazeneca vaccine was primarily a united kingdom vaccine and some other european countries. here, the moderna vaccine is a u.s. vaccine. the research for that vaccine was done at the national institutes of health. moderna is a u.s. company, so that's a u.s. product. it's interesting how that's played out. there's a nationalism there. i talk about that a little bit with anesthesia and the core form was a european invented phenomenon. even though it was actually much more dangerous than two other anesthetic agents, ether and nitrous oxide, it sort of perpetuated longer because there was this nationalistic sense of pride that they were the ones who had invented it. >> do you think that nationalist sense of pride is also driving vaccine use? i mean, i imagine so. right? even though some of these vaccines have worked better than others, it seems that countries who have developed vaccines are sticking with theirs. >> it certainly seems that way. yes. i completely agree. it's interesting. you would think it wouldn't necessarily be that. for example, the vaccine in china, the whole

well, actually, it's good for all are a such vaccine manufacturers astrazeneca mcdonough? sputnik, pfizer, et cetera, to do due diligence with whom they sub contract, the sub testing to it is always important to do the due diligence and random checks that they're doing what they were asked to do. and of course, just very briefly, it's not justifies of vaccine that are so many others. now, i'm, all these other vaccines available on the market would have been put through similar stringent testing procedures. would that indeed indeed, and a half to be. and nevertheless, there's always got to be additional checks and it is not a bad idea to have those checks independent checks and scrutiny always because that way we ensure that the end product is safe and he does what it's meant to do. dr bar upon caressing a clinical lecture, the university of x, the medical school. thank you, sir, have a good day. love to see you. a truck in this next relations had taken a further down turn between australia and france. it comes off for personal text message apparently discussing the french

and astrazeneca foresees revenue of just over 2000000000. now take a look at this chart from bloomberg using data from health intelligence analysts affinity of the 2 plus 1000000000 doses of vaccines produced by pfizer by and take the vast majority shown here and chunky dark blue went to high income countries with less than a $150000000.00 doses to low income countries. that is a 150000000 out of 2000000000. compare that to the vaccine produced by astrazeneca, lower middle income countries, like india, is shown here in light blue received the vast majority of the 2200000000 doses produced. so why does this matter? well, apart from the obvious health reasons, the economist intelligence unit predicts that countries that vaccinate less than 60 percent of their populations by the middle of 2022 will suffer economic losses of over 2 trillion dollars between 20222025. well, it looks like history is now repeating itself, and wealthy countries are already cornering the market for coven 19 pills. the united states has done a $2000000000.00 deal for $

that is a 150000000 out of 2000000000. compare that to the vaccine produced by astrazeneca, lower middle income countries, like india, is shown here in light blue received the vast majority of the 2200000000 doses produced. so why does this matter? well, apart from the obvious health reasons, the economists intelligence unit predicts that countries that vaccinate less than 60 percent of their populations by the middle of 2022 will suffer economic losses of over 2 trillion dollars between 20222025. well, it looks like history is now repeating itself, and wealthy countries are already cornering the market. the coven 19 pills. the united states has done a $2000000000.00 deal for $3000000.00 doses of a rival drug for mug. pfizer has agreements in place to sell its pill to the u. k. australia and south korea by this new pill could be available in early 2022. if regulatory approval is given. probably expecting pushback the company said it would license its pale to the you ends, medicines patent poll to provide low income countries with a cheaper option which is in sharp contrast to its attitud

round, i had pfizer, but if you had astrazeneca it is known the protection was not as good as pfizer. but if you have a pfizer booster, that mix pumps you up not only to where you were before but higher than ever. it pumps you up to have the protection as if you had just had two pfizer doses. our booster rate is higher than other countries and that is protecting us a lot at the moment. obviously you thrive on statistics, that is yourjob, your interest, but how useful would it be to better explain these numbers to the public across europe where we are seeing these protests, this rejection of policies? well, this is always a question asked, but it is more than a matter ofjust explaining the numbers to people. people are against vaccinations for many reasons and no matter how much you explain to them the numbers, some will not take any notice because they are idealogically opposed to them or, particularly in the east, there is a deep mistrust of government and authority. so it is difficult, but i think for people perhaps who are a little bit in the middle, wavering, cautious, to hammer

the first time round, i had pfizer, but if you had astrazeneca it is known the protection was not as good as pfizer. but if you have a pfizer booster, that makes pumps you up not only to where you were before but higher than ever. it pumps you up to have the protection as if you had just had two pfizer doses. our booster rate is higher than other countries and that is really protecting us a lot at the moment. obviously you thrive on statistics, thatis obviously you thrive on statistics, that is yourjob, your interest, but how useful would it be to better explain these numbers to the public across europe, where we are seeing these protests, this rejection of policies? these protests, this re'ection of olicies? ~ , , ., policies? well, this is always the auestion policies? well, this is always the question that _ policies? well, this is always the question that is _ policies? well, this is always the question that is asked, _ policies? well, this is always the question that is asked, but - policies? well, this is always the question that is asked, but it - policies? well, this is alway

astrazeneca and others, we are working well with them. they just need to apply and we are for vaccine combinations. we started the first trials with other vaccines. we are moving forward with the partnership. and now, we believe people are producing a better immune restaurants so we believe vaccine combos are a way of the future. francine: thank you so much. we will talk a little more about politics next time you come on. coming up, payrolls -- u.k. payrolls rise after the government's furlough program. we take a look at what that means for sterling and the bank of england next. this is bloomberg. ♪ tom: welcome back to the open. 42 minutes into the european trading day. a lot of optimism building on record gains in euro. we still have the support from the ecb, christine lagarde saying the monetary policy will remain supportive at least through 2022. and then you have to factor in the higher covid infection rates in europe. but inflationary pressures arguably less acute within the euro zone versus what you are seeing in the u.s. you are

how far are we from what the ceo of astrazeneca was talking about? bhakti: we are still in the midst of a pandemic which means we don't know how to overcome the current version of the disease from the virus. there are still daily deaths and daily limitations. we have some strategies we know to be effective such as social distancing and vaccinating. that has proven to not be enough. the virus continues to evolve. we have been very fortunate so far. it has been a couple of month since delta emerged. lisa: i'm concerned as i look at the numbers. even in areas where there are high vaccination rates, you are seeing surges in the number of cases, south korea in particular with 79% of the adult population with both shots yet you are seeing the highest number of cases diagnosed since the pandemic. does this indicate that the vaccinesdoes this indicate thate vaccines are less effective than we thought they were? bhakti: mortality has not gone up. hospitalization is lacking behind. vaccines are definitely effective. human behavior plays a big part in this viru

cientÍficos de la universidad de oxford desarrollan otra vacuna de astrazeneca en spray. autoridades del reino unido aprobaron la primera pastilla contra el covid. reportera: la ciencia trata de tomarle la delantera al covid—19 luego que en inglaterra aprobaron el primer antiviral en contra del coronavirus. ella ya consume la pÍldora molnupiravir. >> esto reducirÁ mis sÍntomas, por lo que la infecciÓn no se apoderarÁ de mÍ mi acabarÉ en el hospital. reportera: la pÍldora fue aprobada para adultos mayores de 18 aÑos que dieron positivo al covid—19 y tienen al menos un factor de riesgo de desarrollar una enfermedad grave. los mÉdicos hablan de sus ventajas. >> se suministran por cinco dÍas, son mucho mÁs baratas y pueden producirse en masa y distribuirse por todo el mundo. eso es muy importante para un acceso global equitativo a los tratamientos que salvan vidas. reportera: la pÍldora fue diseÑada por la farmacÉutica estadounidense merck. fue diseÑada originalmente para combatir la gripe. >> el covid—19 entra nuestras cÉlulas y se comienza a reproduci